Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Breast Neoplasms 12Glioblastoma 2Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasm Metastasis 1Medulloblastoma 1Inflammatory Breast Neoplasms 1Her2 Positive Metastatic Breast Cancer 1Head and Neck Neoplasms 1HER2 Positive Metastatic Breast Cancer 1Gliosarcoma 1Familial ependymoma 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 23Radiotherapy 15Radiation 7Bevacizumab 6temsirolimus 5Sirolimus 5Radiotherapy, Conformal 5Erlotinib Hydrochloride 5Carmustine 5Carboplatin 5Radiotherapy, Intensity-Modulated 4Everolimus 4Vorinostat 3Irinotecan 3veliparib 2tipifarnib 2plerixafor 2pembrolizumab 2atezolizumab 2Surgical Procedures, Operative 2Sorafenib 2Gefitinib 2Fluorodeoxyglucose F18 2Cilengitide 2Chemotherapy, Adjuvant 2vatalanib 1vandetanib 1terameprocol 1tandutinib 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Gliosarcoma × Lapatinib × Clear all
NCT00099060 2014-01-27

Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 1/2 Completed
24 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡